S‐1 plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial

LESSONS LEARNED. The upregulation of dihydropyrimidine dehydrogenase (DPD) and thymidylate synthase (TS) are important mechanisms of resistance to 5‐fluorouracil (5‐FU) in metastatic colorectal cancer (mCRC) after long exposure to 5‐FU. S‐1 (containing a DPD inhibitor) combined with raltitrexed (a T...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncologist
Hlavní autoři: Chen, Ye, Wu, Jing, Cheng, Ke, Li, Zhi‐Ping, Luo, De‐Yun, Qiu, Meng, Gou, Hong‐Feng, Yi, Cheng, Li, Qiu, Wang, Xin, Yang, Yu, Cao, Dan, Shen, Ya‐Li, Bi, Feng, Liu, Ji‐Yan
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley & Sons, Inc. 2019
Témata:
Clinical Trial Results
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6516113/
https://ncbi.nlm.nih.gov/pubmed/30651398
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0901
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky